Tyra Biosciences, Inc. (TYRA)
| Market Cap | 1.46B +79.4% |
| Revenue (ttm) | n/a |
| Net Income | -148.57M |
| EPS | -2.40 |
| Shares Out | 68.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 243,612 |
| Open | 21.08 |
| Previous Close | 21.07 |
| Day's Range | 20.75 - 21.62 |
| 52-Week Range | 13.35 - 40.65 |
| Beta | 0.75 |
| Analysts | Strong Buy |
| Price Target | 47.45 (+123.93%) |
| Est. Earnings | Nov 13, 2026 |
About TYRA
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for TYRA stock is "Strong Buy." The 12-month stock price target is $47.45, which is an increase of 123.93% from the latest price.
News
Climb Bio added to ‘Analysts Current Favorites’ at Raymond James
Raymond James added Climb Bio (CLYM) to the firm’s “Analysts Current Favorites” list while removing Tyra Biosciences (TYRA). Climb’s setup for both its lead assets – CLYM116 and budoprutug –…
Tyra Biosciences price target lowered to $40 from $50 at Oppenheimer
Oppenheimer lowered the firm’s price target on Tyra Biosciences (TYRA) to $40 from $50 and keeps an Outperform rating on the shares. While SURF302 fell short of the firm’s ablative…
Tyra Biosciences price target lowered to $29 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Tyra Biosciences (TYRA) to $29 from $30 and keeps a Buy rating on the shares. The firm cites dilution from the recent…
Tyra Biosciences prices $400M underwritten offering of common stock and warrants
Tyra Biosciences (TYRA) announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of…
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target lar...
Tyra Biosciences files automatic mixed securities shelf
06:07 EDT Tyra Biosciences (TYRA) files automatic mixed securities shelf
Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Tyra Biosciences (TYRA) to $30 from $45 and keeps a Buy rating on the shares. The company’s SURF302 data missed the bar,…
Tyra Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Dabogratinib demonstrated strong phase II efficacy and safety as an oral therapy for intermediate-risk NMIBC, with a 64% CR rate and 100% ORR in single marker lesions, positioning it as a leading candidate for phase III trials. The drug's favorable safety profile and oral administration address major unmet needs, with expansion into UTUC underway.
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.
Tyra data ‘lukewarm, but not program terminating,’ says Jones
Jones says Tyra Biosciences (TYRA) reported lower than expected initial efficacy data from the Phase II SURF-302 study with dabogratinib in intermediate-risk non-muscle invasive bladder cancer with si...
Tyra Biosciences Transcript: Study result
Initial results from the SURF302 study show oral dabogratinib at 60 mg delivers strong efficacy and safety in intermediate-risk NMIBC, with 79% ORR and 64% CR, and is well-tolerated for chronic dosing. The 60 mg dose is advancing to phase III, aiming to transform standard care by reducing procedural burden and offering a convenient oral option.
Tyra Biosciences Press release: Study result
Tyra Biosciences issued a press release on September 9, 2026, disclosing material business information to investors.
Tyra Biosciences Slides: Study result
Tyra Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Tyra Biosciences reports results from Phase 2 study of SURF302
Tyra Biosciences (TYRA) announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder ca...
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
CARLSBAD, Calif., Sept. 9, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences Slides: Corporate presentation
Tyra Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences price target lowered to $39 from $42 at BofA
BofA lowered the firm’s price target on Tyra Biosciences (TYRA) to $39 from $42 and keeps a Buy rating on the shares after updating the firm’s model to reflect the…
Tyra Biosciences price target lowered to $42 from $44 at Jefferies
Jefferies analyst Maury Raycroft lowered the firm’s price target on Tyra Biosciences (TYRA) to $42 from $44 and keeps a Buy rating on the shares. Tyra’s Q2 update “modestly pushes…
Tyra Biosciences delayed cancer data by one month, says JonesResearch
JonesResearch analyst Boris Peaker says that with its Q2 earnings report, Tyra Biosciences (TYRA) announced that the update from the Phase II SURF-302 clinical readout with dabogratinib in FGFR3-alter...
Tyra Biosciences falls 20% after pushing data readout to September from August
The stock in midday trading is down $6.39 to $26.15.
Tyra Biosciences reports Q2 EPS (69c), consensus (64c)
As of June 30 TYRA had cash, cash equivalents and marketable securities of $353.9M. The Company’s current cash, cash equivalents and marketable securities are expected to allow TYRA to execute…
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose leve...
Tyra Biosciences Earnings release: Q2 2026
Tyra Biosciences released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.